Determinants of buildup of the toxic dopamine metabolite DOPAL in Parkinson's disease

Journal of Neurochemistry

Volumn 126, Issue 5, 2013, Pages 591-603

  Goldstein, David S ^a   Sullivan, Patti ^a   Holmes, Courtney ^a   Miller, Gary W ^b   Alter, Shawn ^b   Strong, Randy ^c   Mash, Deborah C ^d   Kopin, Irwin J ^a   Sharabi, Yehonatan ^a,e  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b EMORY UNIVERSITY   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^e TEL AVIV UNIVERSITY   (Israel)

Author keywords

DOPAC; DOPAL; dopamine; DOPET; monoamine oxidase; Parkinson's disease

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; 3,4 DIHYDROXYPHENYLETHYLENE GLYCOL; ALDEHYDE DEHYDROGENASE; CATECHOL DERIVATIVE; CATECHOLAMINE; DOPA; NORADRENALIN; VESICULAR MONOAMINE TRANSPORTER 2;

AGED; ALDH1A1 GENE; ALDH2 GENE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOPSY; BRAIN REGION; BRAIN TISSUE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE BRAIN LEVEL; DOPAMINE UPTAKE; ENZYME ACTIVITY; FEMALE; GENE; HUMAN; HUMAN TISSUE; MALE; MOUSE; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; PUTAMEN;

DOPAC; DOPAL; DOPAMINE; DOPET; MONOAMINE OXIDASE; PARKINSON'S DISEASE;

3,4-DIHYDROXYPHENYLACETIC ACID; AGED; ALDEHYDE DEHYDROGENASE; ANIMALS; BRAIN CHEMISTRY; CATECHOLS; DIHYDROXYPHENYLALANINE; DOPAMINE; FEMALE; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PARKINSON DISEASE; PUTAMEN; VESICULAR MONOAMINE TRANSPORT PROTEINS;

MUS; MUS MUSCULUS;

EID: 84883195985     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/jnc.12345     Document Type: Article

References (52)

1. Anderson D. G., Mariappan S. V., Buettner G. R., and, Doorn J. A., (2011) Oxidation of 3,4-dihydroxyphenylacetaldehyde, a toxic dopaminergic metabolite, to a semiquinone radical and an ortho-quinone. J. Biol. Chem. 286, 26978-26986.
2. Bohnen N. I., Albin R. L., Koeppe R. A., Wernette K. A., Kilbourn M. R., Minoshima S., and, Frey K. A., (2006) Positron emission tomography of monoaminergic vesicular binding in aging and Parkinson disease. J. Cereb. Blood Flow Metab. 26, 1198-1212.
3. Bonifacio M. J., Archer M., Rodrigues M. L., Matias P. M., Learmonth D. A., Carrondo M. A., and, Soares-Da-Silva P., (2002) Kinetics and crystal structure of catechol-o-methyltransferase complex with co-substrate and a novel inhibitor with potential therapeutic application. Mol. Pharmacol. 62, 795-805.
4. Burke W. J., Li S. W., Williams E. A., Nonneman R., and, Zahm D. S., (2003) 3,4-Dihydroxyphenylacetaldehyde is the toxic dopamine metabolite in vivo: implications for Parkinson's disease pathogenesis. Brain Res. 989, 205-213.
5. Burke W. J., Li S. W., Chung H. D., et al,. (2004) Neurotoxicity of MAO metabolites of catecholamine neurotransmitters: role in neurodegenerative diseases. Neurotoxicology 25, 101-115.
6. Burke W. J., Kumar V. B., Pandey N., et al,. (2008) Aggregation of alpha-synuclein by DOPAL, the monoamine oxidase metabolite of dopamine. Acta Neuropathol. 115, 193-203.
7. Caudle W. M., Richardson J. R., Wang M. Z., et al,. (2007) Reduced vesicular storage of dopamine causes progressive nigrostriatal neurodegeneration. J. Neurosci. 27, 8138-8148.
8. DelleDonne A., Klos K. J., Fujishiro H., et al,. (2008) Incidental Lewy body disease and preclinical Parkinson disease. Arch. Neurol. 65, 1074-1080.
9. Duester G., (2001) Genetic dissection of retinoid dehydrogenases. Chem. Biol. Interact. 130-132, 469-480.
10. Ehringer H., and, Hornykiewicz O., (1960) Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system. Wien. Klin. Wochenschr. 38, 1236-1239.
11. Eisenhofer G., Friberg P., Rundqvist B., Quyyumi A. A., Lambert G., Kaye D. M., Kopin I. J., Goldstein D. S., and, Esler M. D., (1996) Cardiac sympathetic nerve function in congestive heart failure. Circulation 93, 1667-1676.
12. Eisenhofer G., Kopin I. J., and, Goldstein D. S., (2004) Catecholamine metabolism: a contemporary view with implications for physiology and medicine. Pharmacol. Rev. 56, 331-349.
13. Fitzmaurice A. G., Rhodes S. L., Lulla A., et al,. (2012) Aldehyde dehydrogenase inhibition as a pathogenic mechanism in Parkinson disease. Proc. Natl Acad. Sci. USA 110, 636-641.
14. Gainetdinov R. R., Fumagalli F., Wang Y. M., Jones S. R., Levey A. I., Miller G. W., and, Caron M. G., (1998) Increased MPTP neurotoxicity in vesicular monoamine transporter 2 heterozygote knockout mice. J. Neurochem. 70, 1973-1978.
15. Galter D., Buervenich S., Carmine A., Anvret M., and, Olson L., (2003) ALDH1 mRNA: presence in human dopamine neurons and decreases in substantia nigra in Parkinson's disease and in the ventral tegmental area in schizophrenia. Neurobiol. Dis. 14, 637-647.
16. Gjedde A., Reith J., Dyve S., Leger G., Guttman M., Diksic M., Evans A., and, Kuwabara H., (1991) Dopa decarboxylase activity of the living human brain. Proc. Natl Acad. Sci. USA 88, 2721-2725.
17. Goldstein D. S., (2012) Stress, allostatic load, catecholamines, and other neurotransmitters in neurodegenerative diseases. Cell. Mol. Neurobiol. 32, 661-666.
18. Goldstein D. S., Katzper M., Linares O. A., and, Kopin I. J., (2002) Kinetic model for the fate of the sympathoneural imaging agent 6-[18F]fluorodopamine in the human heart: a novel means to assess cardiac sympathetic neuronal function. Naunyn-Schmiedeberg's Arch. Pharmacol. 365, 38-49.
19. Goldstein D. S., Sullivan P., Holmes C., Kopin I. J., Basile M. J., and, Mash D. C., (2011) Catechols in post-mortem brain of patients with Parkinson disease. Eur. J. Neurol. 18, 703-710.
20. Goldstein D. S., Holmes C., and, Sharabi Y., (2012a) Cerebrospinal fluid biomarkers of central catecholamine deficiency in Parkinson's disease and other synucleinopathies. Brain 135, 1900-1913.
21. Goldstein D. S., Sullivan P., Cooney A., Jinsmaa Y., Sullivan R., Gross D. J., Holmes C., Kopin I. J., and, Sharabi Y., (2012b) Vesicular uptake blockade generates the toxic dopamine metabolite 3,4-dihydroxyphenylacetaldehyde in PC12 Cells: relevance to the pathogenesis of Parkinson disease. J. Neurochem. 123, 932-943.
22. Grunblatt E., Zehetmayer S., Jacob C. P., Muller T., Jost W. H., and, Riederer P., (2010) Pilot study: peripheral biomarkers for diagnosing sporadic Parkinson's disease. J. Neural. Transm. 117, 1387-1393.
23. Guillot T. S., and, Miller G. W., (2009) Protective actions of the vesicular monoamine transporter 2 (VMAT2) in monoaminergic neurons. Mol. Neurobiol. 39, 149-170.
24. Guillot T. S., Shepherd K. R., Richardson J. R., Wang M. Z., Li Y., Emson P. C., and, Miller G. W., (2008) Reduced vesicular storage of dopamine exacerbates methamphetamine-induced neurodegeneration and astrogliosis. J. Neurochem. 106, 2205-2217.
25. Holmes C., Eisenhofer G., and, Goldstein D. S., (1994) Improved assay for plasma dihydroxyphenylacetic acid and other catechols using high-performance liquid chromatography with electrochemical detection. J. Chromatogr. B Biomed. Appl. 653, 131-138.
26. Holmes C., Whittaker N., Heredia-Moya J., and, Goldstein D. S., (2010) Contamination of the norepinephrine prodrug droxidopa by dihydroxyphenylacetaldehyde. Clin. Chem. 56, 832-838.
27. Hornykiewicz O., (1998) Biochemical aspects of Parkinson's disease. Neurology 51, S2-S9.
28. Li S. W., Lin T. S., Minteer S., and, Burke W. J., (2001) 3,4-Dihydroxyphenylacetaldehyde and hydrogen peroxide generate a hydroxyl radical: possible role in Parkinson's disease pathogenesis. Brain Res. Mol. Brain Res. 93, 1-7.
29. Liu H. Q., Zhu X. Z., and, Weng E. Q., (2005) Intracellular dopamine oxidation mediates rotenone-induced apoptosis in PC12 cells. Acta Pharmacol. Sin. 26, 17-26.
30. Mandel S., Grunblatt E., Riederer P., Amariglio N., Jacob-Hirsch J., Rechavi G., and, Youdim M. B., (2005) Gene expression profiling of sporadic Parkinson's disease substantia nigra pars compacta reveals impairment of ubiquitin-proteasome subunits, SKP1A, aldehyde dehydrogenase, and chaperone HSC-70. Ann. N. Y. Acad. Sci. 1053, 356-375.
31. Marchitti S. A., Deitrich R. A., and, Vasiliou V., (2007) Neurotoxicity and metabolism of the catecholamine-derived 3,4-dihydroxyphenyla cetaldehyde and 3,4-dihydroxyphenylglycolaldehyde: the role of aldehyde dehydrogenase. Pharmacol. Rev. 59, 125-150.
32. Mattammal M. B., Haring J. H., Chung H. D., Raghu G., and, Strong R., (1995) An endogenous dopaminergic neurotoxin: implication for Parkinson's disease. Neurodegeneration 4, 271-281.
33. Miller G. W., Erickson J. D., Perez J. T., Penland S. N., Mash D. C., Rye D. B., and, Levey A. I., (1999) Immunochemical analysis of vesicular monoamine transporter (VMAT2) protein in Parkinson's disease. Exp. Neurol. 156, 138-148.
34. Miller G. W., Wang Y. M., Gainetdinov R. R., and, Caron M. G., (2001) Dopamine transporter and vesicular monoamine transporter knockout mice: implications for Parkinson's disease. Methods Mol. Med. 62, 179-190.
35. Molochnikov L., Rabey J. M., Dobronevsky E., et al,. (2012) A molecular signature in blood identifies early Parkinson's disease. Mol. Neurodegener. 7, 26.
36. Okamura N., Villemagne V. L., Drago J., et al,. (2010) In vivo measurement of vesicular monoamine transporter type 2 density in Parkinson disease with (18)F-AV-133. J. Nucl. Med. 51, 223-228.
37. Panneton W. M., Kumar V. B., Gan Q., Burke W. J., and, Galvin J. E., (2010) The neurotoxicity of DOPAL: behavioral and stereological evidence for its role in Parkinson disease pathogenesis. PLoS ONE 5, e15251.
38. Polymeropoulos M. H., Lavedan C., Leroy E., et al,. (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276, 2045-2047.
39. Raffel D. M., Koeppe R. A., Little R., Wang C. N., Liu S., Junck L., Heumann M., and, Gilman S., (2006) PET measurement of cardiac and nigrostriatal denervation in parkinsonian syndromes. J. Nucl. Med. 47, 1769-1777.
40. Rees J. N., Florang V. R., Anderson D. G., and, Doorn J. A., (2007) Lipid peroxidation products inhibit dopamine catabolism yielding aberrant levels of a reactive intermediate. Chem. Res. Toxicol. 20, 1536-1542.
41. Rees J. N., Florang V. R., Eckert L. L., and, Doorn J. A., (2009) Protein reactivity of 3,4-dihydroxyphenylacetaldehyde, a toxic dopamine metabolite, is dependent on both the aldehyde and the catechol. Chem. Res. Toxicol. 22, 1256-1263.
42. Sai Y., Wu Q., Le W., Ye F., Li Y., and, Dong Z., (2008) Rotenone-induced PC12 cell toxicity is caused by oxidative stress resulting from altered dopamine metabolism. Toxicol. In Vitro 22, 1461-1468.
43. Satake W., Nakabayashi Y., Mizuta I., et al,. (2009) Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease. Nat. Genet. 41, 1303-1307.
44. Singleton A. B., Farrer M., Johnson J., et al,. (2003) alpha-Synuclein locus triplication causes Parkinson's disease. Science 302, 841.
45. Staal R. G., and, Sonsalla P. K., (2000) Inhibition of brain vesicular monoamine transporter (VMAT2) enhances 1-methyl-4-phenylpyridinium neurotoxicity in vivo in rat striata. J. Pharmacol. Exp. Ther. 293, 336-342.
46. Taylor T. N., Caudle W. M., Shepherd K. R., Noorian A., Jackson C. R., Iuvone P. M., Weinshenker D., Greene J. G., and, Miller G. W., (2009) Nonmotor symptoms of Parkinson's disease revealed in an animal model with reduced monoamine storage capacity. J. Neurosci. 29, 8103-8113.
47. Tong J., Boileau I., Furukawa Y., Chang L.-J., Wilson A. A., Houle S., and, Kish S. J., (2011) Distribution of vesicular monoamine transporter 2 protein in human brain: implications for brain imaging studies. J. Cereb. Blood Flow Metab. 31, 2065-2075.
48. Ulusoy A., Bjorklund T., Buck K., and, Kirik D., (2012) Dysregulated dopamine storage increases the vulnerability to alpha-synuclein in nigral neurons. Neurobiol. Dis. 47, 367-377.
49. Wang Y. M., Gainetdinov R. R., Fumagalli F., Xu F., Jones S. R., Bock C. B., Miller G. W., Wightman R. M., and, Caron M. G., (1997) Knockout of the vesicular monoamine transporter 2 gene results in neonatal death and supersensitivity to cocaine and amphetamine. Neuron 19, 1285-1296.
50. Werner C. J., Heyny-von Haussen R., Mall G., and, Wolf S., (2008) Proteome analysis of human substantia nigra in Parkinson's disease. Proteome Sci. 6, 8.
51. Wey M., Fernandez E., Martinez P. A., Sullivan P., Goldstein D. S., and, Strong R., (2012) Neurodegeneration and motor dysfunction in mice lacking cytosolic and mitochondrial aldehyde dehydrogenases: implications for Parkinson's disease. PLoS ONE 7, e31522.
52. Yoritaka A., Hattori N., Uchida K., Tanaka M., Stadtman E. R., and, Mizuno Y., (1996) Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease. Proc. Natl Acad. Sci. USA 93, 2696-2701.